CorMedix Inc. (CRMD)
Summary
CorMedix (CRMD) Upgraded to Buy: Here's Why
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
CorMedix Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 214,860 | $1.69M | $1.81M | $124,619.81 | 7.39% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,500 | $17,445 | $12,645 | -$4,800 | -27.52% |
| ME Matthew Ellis Planning Directions Inc | 20,000 | $126,000 | $168,600 | $42,600 | 33.81% |
| BG Bart Gancher Intech Investment Management LLC | 18,847 | $124,054.99 | $141,917.91 | $17,862.92 | 14.4% |
| KAC Kimberly A. Clarke Stoneridge Investment Partners LLC | 13,129 | $99,000 | $97,285.89 | -$1,714.11 | -1.73% |
CorMedix Inc. (CRMD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CorMedix Inc. ever had a stock split?
CorMedix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joseph Todisco CEO | NASDAQ (NMS) Exchange | 21900C308 CUSIP |
| US Country | 191 Employees | 26 Mar 2019 Last Dividend | 26 Mar 2019 Last Split | 25 Mar 2010 IPO Date |
Overview
CorMedix Inc. is a biopharmaceutical company committed to the development and commercialization of novel therapeutic products aimed at the prevention and treatment of infectious and inflammatory diseases, primarily in the United States. Originally founded as Picton Holding Company, Inc., the organization underwent a name change to CorMedix Inc. in January 2007, symbolizing a focused shift towards its core mission in the biopharmaceutical arena. Incorporated in 2006, CorMedix has established its operational base in Berkeley Heights, New Jersey, from where it spearheads its research, development, and commercialization efforts. The company's strategic initiatives are directed towards addressing the unmet medical needs of patients, particularly those suffering from kidney failure, through innovative solutions designed to enhance patient care and outcomes.
Products and Services
CorMedix Inc. is actively involved in the development and prospective commercialization of a leading product candidate, alongside engagement in research aimed at expanding its product portfolio. Detailed below are the key focus areas of its product development efforts:
- DefenCath: CorMedix's flagship product candidate, DefenCath, is an antimicrobial catheter lock solution designed to significantly reduce the incidence of catheter-related bloodstream infections among adult patients with kidney failure. This innovative solution represents a proactive approach to healthcare, aiming to improve patient outcomes and quality of life by combating the challenges posed by bloodstream infections, which are a common complication in patients undergoing dialysis treatments.
